Skip to main content

Table 1 Included diseases and drug classes for the ISTOP-ADE study

From: Effectiveness of a computerized drug-monitoring program to detect and prevent adverse drug events and medication non-adherence in outpatient ambulatory care: study protocol of a randomized controlled trial

Disease entity

Drug classes included

Congestive heart failure

Angiotensin-converting enzyme inhibitors, angiotensin II receptor antagonists, hydralazine, mineralocorticoid (aldosterone) receptor antagonists, nitrate, diuretic, cardiac glycoside, β-adrenergic blocking agents

Diabetes mellitus

Sulfonylurea/insulin secretagogue, biguanide, A-glucosidase inhibitor thiazolidinedione, incretin therapy (dipeptidyl peptidase-4 inhibitor), insulin

Hypertension

β-adrenergic blocking agents, diuretic, calcium-channel blocking agents, angiotensin-converting enzyme inhibitors, angiotensin II receptor antagonists, nitrate, central α-agonists

Coronary artery disease

β-adrenergic blocking agents, statin, calcium-channel blocking agents, angiotensin-converting enzyme inhibitors, angiotensin II receptor antagonists, nitrate, acetylsalicylic acid, clopidogrel

Dyslipidemia

Statin, cholestyramine resin, fibric acid derivatives, niacin derivative, cholesterol absorption inhibitor

Cerebrovascular disease

Acetylsalicylic acid, clopidogrel, statin, dypiramidole

Atrial fibrillation

β-adrenergic blocking agents, cardiac glycoside, class III anti-arrhythmics, class Ic anti-arrhythmics, calcium-channel blocking agents, vitamin K antagonist, thrombin inhibitor, Acetylsalicylic acid

Chronic kidney disease

Angiotensin-converting enzyme inhibitors, angiotensin II receptor antagonists, thiazide diuretic, β-adrenergic blocking agents, calcium-channel blocking agents

Chronic obstructive pulmonary disease

Short-acting bronchodilators, long-acting bronchodilators, phosphodiesterase type-4 inhibitors, combination inhaled corticosteroids and long-acting bronchodilators, theophylline

Depression

Serotonin-specific reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, quetiapine, bupropion, trazodone, mirtazapine

Dementia

Parasympathomimetic (cholinergic)

Autoimmune conditions

Corticosteroids

Seizures, chronic pain

Anticonvulsants

  1. Participants will be enrolled in the ISTOP-ADE study if they have an incident prescription for a high-risk medication. We define high-risk prescriptions as medications commonly used to prevent progression or complications related to key conditions (disease entities). The selected drug classes have an important impact on outcomes or they have been shown to have a high frequency of ADEs.
Back to article page

Trials

ISSN: 1745-6215